Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › EYPT

EyePoint

EYPT Lead: Phase 3 8 Biotech Distilled articles ↓ 29 filings & releases ↓ Cash $110M (Jun 30, 2026) ↓ 8 verdicts ↓ 4 timing quotes ↓
Ophthalmology Small Molecule

Market cap $31.0M 86.2M shares (10-Q, Jul 31, 2026) × $0.360 close Nov 6, 2026

Most recent annual filing: 2026-03-05

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. Workforce reduction corporate update1H 2027Workforce reduction corporate update, 1H 2027, routine
  2. COMO/CAPRI DME topline4Q 2027COMO/CAPRI DME topline, 4Q 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (2 active programs)

Technology platforms

Durasert E

Next-generation bioerodible intravitreal drug delivery technology designed to provide sustained release of drug for at least six months without free-floating drug particles; used as the delivery vehicle for vorolanib in DURAVYU for serious retinal diseases including wet AMD and DME.

Discontinued (1)

Capital (as filed)

Cash
$110M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$70.0M Jun 30, 2026
Operating cash flow
−$62.3M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$118M cash, runway Q4 2027 per the update of Oct 19, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (8)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (8 calls)

Every verdict Biotech Distilled has published on EyePoint, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-05-01 Buy core EyePoint Pharmaceuticals (EYPT) - Scientific Deep Dive for DURAVYU and Pipeline Products Asymmetric binary setup ahead of mid-2026 Phase 3 readouts, backed by clean Phase 2 data, multi-MOA science, and a cash runway that eliminates pre-data dilution risk.
  2. 2026-05-07 Buy core UPDATE: EyePoint (EYPT) — Q1 2026 Status Check Into the LUGANO Window Interim masked Phase 3 safety remains clean across 900+ patients and catalyst calendar is intact, though cash burn is higher than originally modeled.
  3. 2026-07-17 Buy core UPDATE: EyePoint (EYPT) — The DOJ Overhang Clears for Pocket Change DOJ investigation resolved for a rounding error (~$4.85M), narrowing the bear case to just the unresolved Watertown Warning Letter ahead of imminent LUGANO topline.
  4. 2026-07-30 Buy core UPDATE: EyePoint (EYPT) - The Binary Event Now Has a Month LUGANO topline tightened to August 2026, DSMC continuation across 1,400+ patients removes the most common failure mode, and DME enrollment completed ahead of schedule.
  5. 2026-08-06 Buy core UPDATE: EyePoint (EYPT) - The Last Quarter Before the Verdict Clinical thesis and catalyst calendar unchanged, but balance sheet is thinner than originally modeled after ATM sales and higher burn; LUGANO print is weeks away.
  6. 2026-08-17 Hold UPDATE: EyePoint (EYPT) - LUGANO Missed. Nine Patients Broke the Thesis. LUGANO missed the primary endpoint on the full dataset; asset is damaged but not dead as LUCIA (Q4 2026) becomes the new binary event, though financing overhang is now the near-term killer.
  7. 2026-09-10 Hold UPDATE: EyePoint (EYPT) - They Ran the Analysis I Asked For Expanded LUGANO analyses strengthen the asymmetric-cohort explanation (no 10-14 letter imbalance, GA growth matching fellow eye), nudging LUCIA odds to 55/45, but financing overhang and Watertown remain unresolved.
  8. 2026-10-20 Avoid UPDATE: EyePoint (EYPT) - Zero for Two LUCIA missed non-inferiority outright with a normal control arm, wet AMD program shut down, efficacy failure confirmed as structural rather than statistical bad luck, and remaining cash is being spent toward a below-even-odds DME binary more than a year away.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (4 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (29)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 19, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

14 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)